Lack of detectable allergenicity of transgenic maize and soya samples
Lack of detectable allergenicity of transgenic maize and soya samples
复制标题
DOI：
10.1016/j.jaci.2005.04.014
复制
发表时间：
2005-08-01
影响因子：
14.2
通讯作者：
Oliveira, MM
中科院分区：
文献类型：
--
作者：
Batista, R;Nunes, B;Oliveira, MM
背景：转基因植物食品的安全问题是其能否被接受进入食品供应的关键。转基因食品中新引入的蛋白质的潜在致敏性是一个主要的安全问题。目的：我们试图监测，在潜在的敏感人群中，5个转基因材料的致敏性影响，这些材料来自没有致敏潜力的来源，并已在欧盟的商业化。研究方法：我们已经进行了皮肤点刺试验与蛋白质提取物制备转基因玉米（MON 810，Bt 11，T25，Bt 176）和大豆（Roundup Ready）样品和非转基因对照样品中的2个敏感组：儿童与食物和吸入过敏和个人哮喘鼻炎。我们还测试了食物过敏患者血清的IgE免疫印迹反应性大豆（Roundup Ready）和玉米（MON 810，Bt 11，Bt 176）样品，以及纯转基因蛋白（CryIA[B]和CP 4 5-烯醇式乙酰莽草酸3-磷酸合酶）。测试的志愿者中没有一个呈现出可检测到的IgE抗体对纯转基因protein.Conclusion：在测试中的转基因产品似乎是安全的过敏潜力。我们建议上市后测试作为一个重要的筛选策略，推定过敏致敏蛋白质引入转基因植物。
Background: The safety issues regarding foods derived from genetically modified (GM) plants are central to their acceptance into the food supply. The potential allergenicity of proteins newly introduced in GM foods is a major safety concern.Objective: We sought to monitor, in potentially sensitive human populations, the allergenicity effects of 5 GM materials obtained from sources with no allergenic potential and already under commercialization in the European Union. Methods: We have performed skin prick tests with protein extracts prepared from transgenic maize (MON810, Bt11, T25, Bt176) and soya (Roundup Ready) samples and from nontransgenic control samples in 2 sensitive groups: children with food and inhalant allergy and individuals with asthma-rhinitis. We have also tested IgE immunoblot reactivity of sera from patients with food allergy to soya (Roundup Ready) and maize (MON810, Bt11, Bt176) samples, as well as to the pure transgenic proteins (CryIA[b] and CP4 5-enolpyruvylshikimate3-phosphate synthase).Results: None of the individuals undergoing tests reacted differentially to the transgenic and nontransgenic samples under study. None of the volunteers tested presented detectable IgE antibodies against pure transgenic proteins.Conclusion: The transgenic products under testing seem to be safe in terms of allergenic potential. We propose postmarket testing as an important screening strategy for putative allergic sensitization to proteins introduced in transgenic plants.